After updating investors on its wide-ranging gene therapy research program at a key industry conference early in the month,shares of bluebird bio At the J.P. Morgan Healthcare Conference in early January, Bluebird Bio’s management outlined how it hopes to transform treating rare disease, including cerebral ALD , transfusion dependent beta thalassemia , and sickle cell disease. The company provided an outlook for 2022 that includes a goal of having two gene therapies on the market, two other therapies near commercialization, and four or more research programs in clinical studies.